Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06741579 · ClinicalTrials.gov registry record · Phase 3
Mechanisms of Stimulation for Pain Alleviation
A Phase 3 study of Chronic Neuropathic Pain and Peripheral Nerve Stimulation, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 148
- Enrollment target
- 1
- Study location
NCT06741579: Recruiting Phase 3 study of Chronic Neuropathic Pain and Peripheral Nerve Stimulation, sponsored by Stanford University.
NCT06741579 is a Phase 3 study of Chronic Neuropathic Pain and Peripheral Nerve Stimulation that is actively recruiting participants, run by Stanford University. The registered enrollment target is 148 participants, above the 40-participant average among 3 other Chronic Neuropathic Pain trials with a reported enrollment target (270% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06741579, a Phase 3 study of Chronic Neuropathic Pain and Peripheral Nerve Stimulation, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 148 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a mechanistic randomized controlled trial of patients with chronic neuropathic pain (CNP) in the lower back, pelvis, and lower extremities, randomized to conventional medical management (CMM) or combined CMM and peripheral nerve stimulation therapy (PNS+CMM). Our goal is to compare treatment outcomes and trial response rate across the control and interventional device groups.
Primary Outcome
We will compare the mean of a three-day diary of numeric rating scale of pain (NRS) intensity scores (0-10 scale) at baseline to the mean of a three-day diary of NRS scores at 3 months comparing all participants randomized to CMM vs. PNS+CMM.
Conditions Studied
Interventions
- DEVICE Peripheral Nerve Stimulation
- PROCEDURE Conventional Care Regimen
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2025-09-26 |
| Est. Completion | 2028-11-01 |
| Phase | Phase 3 |
What NCT06741579 shows while recruiting
NCT06741579 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, above the 40-participant average among 3 other Chronic Neuropathic Pain trials with a reported enrollment target (270% higher).
The record links to 3 conditions, with Chronic Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Peripheral Nerve Stimulation is the first listed.
NCT06741579 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06741579 about?
NCT06741579 is a clinical study titled "Mechanisms of Stimulation for Pain Alleviation". This is a mechanistic randomized controlled trial of patients with chronic neuropathic pain (CNP) in the lower back, pelvis, and lower extremities, randomized to conventional medical management (CMM) or combined CMM and peripheral nerve stimulation therapy (PNS+CMM). Our goal is to compare treatment...
What is the current status of trial NCT06741579?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 148 participants. The study started on 2025-09-26. Estimated completion is 2028-11-01.
What conditions does trial NCT06741579 study?
This clinical trial studies the following conditions: Chronic Neuropathic Pain, Peripheral Nerve Stimulation, Chronic Neuropathic Pain in the Low Back and Legs.
What interventions are being tested in trial NCT06741579?
The interventions under investigation include: Peripheral Nerve Stimulation (DEVICE), Conventional Care Regimen (PROCEDURE).
Who is sponsoring clinical trial NCT06741579?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06741579 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Dose Naltrexone for Pain in Patients With HIV
RECRUITING · Phase 4
-
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
RECRUITING · Phase 1
-
Transcranial Magnetic Stimulation for Chronic Neuropathic Pain
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI